Complete financial analysis of InterCure Ltd. (INCR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of InterCure Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lexston Life Sciences Corp. (LEXTF) Income Statement Analysis – Financial Results
- XMReality AB (publ) (XMR.ST) Income Statement Analysis – Financial Results
- Oculus VisionTech, Inc. (OVTZ) Income Statement Analysis – Financial Results
- DT Cloud Star Acquisition Corporation Ordinary Shares (DTSQ) Income Statement Analysis – Financial Results
- Taurus Armas S.A. (TASA3.SA) Income Statement Analysis – Financial Results
InterCure Ltd. (INCR)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.intercure.co
About InterCure Ltd.
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 355.55M | 388.68M | 219.68M | 65.04M | 8.93M | 0.00 | 0.00 | 0.00 | 1.40M | 5.65M | 8.25M | 8.47M | 12.07M | 13.23M |
| Cost of Revenue | 250.46M | 233.60M | 128.55M | 33.06M | 7.45M | 0.00 | 0.00 | 0.00 | 538.71K | 1.87M | 1.84M | 1.99M | 2.89M | 3.13M |
| Gross Profit | 105.10M | 155.08M | 91.13M | 31.98M | 1.48M | 0.00 | 0.00 | 0.00 | 862.71K | 3.78M | 6.41M | 6.47M | 9.18M | 10.10M |
| Gross Profit Ratio | 29.56% | 39.90% | 41.48% | 49.17% | 16.57% | 0.00% | 0.00% | 0.00% | 61.56% | 66.85% | 77.67% | 76.44% | 76.03% | 76.34% |
| Research & Development | 388.00K | 632.00K | 1.24M | 1.58M | 1.71M | 0.00 | 0.00 | 0.00 | 0.00 | 50.62K | 104.48K | 351.18K | 844.93K | 1.03M |
| General & Administrative | 64.30M | 91.72M | 30.73M | 17.86M | 76.36M | 9.81M | 1.12M | 1.40M | 2.02M | 3.17M | 2.88M | 4.52M | 5.16M | 8.59M |
| Selling & Marketing | 21.94M | 5.60M | 23.21M | 8.44M | 2.69M | 0.00 | 0.00 | 0.00 | 167.86K | 2.54M | 5.22M | 3.62M | 4.46M | 4.97M |
| SG&A | 86.24M | 97.32M | 53.94M | 26.30M | 79.05M | 9.81M | 1.12M | 1.40M | 2.19M | 5.71M | 8.10M | 8.14M | 9.63M | 13.56M |
| Other Expenses | 60.04M | 4.20M | 2.93M | 745.00K | 853.00K | 0.00 | 24.33K | 369.27K | 89.78K | 140.18K | 142.78K | 156.91K | 510.00K | 510.91K |
| Operating Expenses | 146.66M | 102.15M | 58.11M | 28.62M | 81.62M | 9.81M | 1.12M | 1.40M | 2.39M | 5.90M | 8.34M | 8.65M | 10.98M | 15.10M |
| Cost & Expenses | 397.12M | 335.76M | 186.65M | 61.68M | 89.06M | 9.81M | 1.12M | 1.40M | 2.92M | 7.77M | 10.19M | 10.64M | 13.87M | 18.23M |
| Interest Income | 4.55M | 844.00K | 130.00K | 21.00K | 141.00K | 0.00 | 0.00 | 0.00 | 19.52K | 0.00 | 0.00 | 3.74K | -68.51K | 3.55K |
| Interest Expense | 24.22M | 14.69M | 5.05M | 264.00K | 1.84M | 1.03M | 639.51K | 411.59K | 0.00 | 0.00 | 86.69K | 1.83M | 7.08M | 8.81M |
| Depreciation & Amortization | 13.17M | 11.70M | 7.39M | 3.25M | 23.00K | 10.00K | 4.00K | 979.00K | 870.52K | 23.36K | 142.78K | 112.08K | 224.55K | 496.72K |
| EBITDA | -23.90M | 64.50M | 37.45M | -34.53M | -21.20M | -10.12M | -1.09M | 0.00 | -1.64M | -3.77M | -1.88M | 45.38M | -1.65M | -4.60M |
| EBITDA Ratio | -6.72% | 16.59% | 17.11% | 2.78% | -237.55% | 0.00% | 0.00% | 0.00% | -116.99% | -39.08% | -22.79% | -25.10% | -13.65% | -34.76% |
| Operating Income | -41.57M | 52.80M | 28.19M | -1.45M | -80.14M | -10.62M | -3.98M | 1.20M | -2.51M | 2.67M | -1.94M | -2.17M | -1.80M | -5.00M |
| Operating Income Ratio | -11.69% | 13.58% | 12.83% | -2.23% | -897.78% | 0.00% | 0.00% | 0.00% | -179.11% | 47.28% | -23.47% | -25.67% | -14.95% | -37.82% |
| Total Other Income/Expenses | -19.72M | -6.79M | -9.45M | 92.00K | -3.15M | -2.18M | -1.28M | -938.57K | 627.79K | -1.12M | -4.67M | 45.62M | -4.96M | -7.51M |
| Income Before Tax | -61.29M | 43.84M | 18.74M | -38.31M | -3.67M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.76M | -12.52M |
| Income Before Tax Ratio | -17.24% | 11.28% | 8.53% | -58.90% | -41.10% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.01% | -94.64% |
| Income Tax Expense | 2.25M | 93.00K | 11.44M | -2.27M | -673.00K | -1.15M | 663.84K | 3.05M | -780.73K | 0.00 | 87.06K | 1.83M | 41.87K | 46.12K |
| Net Income | -61.96M | 44.82M | 7.30M | -36.04M | -3.00M | -12.80M | -5.26M | 265.42K | -1.88M | -3.79M | -6.61M | 43.44M | -6.80M | -12.56M |
| Net Income Ratio | -17.43% | 11.53% | 3.32% | -55.42% | -33.56% | 0.00% | 0.00% | 0.00% | -133.98% | -67.13% | -80.08% | 512.92% | -56.35% | -94.98% |
| EPS | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 711.66 | -23.15 | -42.77 |
| EPS Diluted | -1.36 | 0.99 | 0.16 | -1.42 | -0.13 | -0.62 | -0.31 | 0.02 | -0.21 | -2.34 | -4.36 | 585.98 | -23.15 | -42.77 |
| Weighted Avg Shares Out | 45.56M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 16.78M | 12.58M | 8.85M | 1.62M | 1.51M | 380.97K | 293.74K | 293.74K |
| Weighted Avg Shares Out (Dil) | 45.57M | 45.35M | 46.92M | 25.40M | 23.30M | 20.60M | 17.11M | 12.90M | 8.85M | 1.62M | 1.51M | 462.21K | 293.74K | 293.74K |
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company
InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
NEW YORK and HERZLIYA, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd . (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the six months ended June 30, 2024. All amounts...
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading vertically integrated medical cannabis company outside of North America, is announcing a new strategic agreement with Cookies, the globally recognized cannabis...
InterCure: A Cannabis Industry Leader Still Flying Under The Radar
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a...
InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc), the leading medical cannabis company outside of North America, today announced that it will participate in the Canaccord Genuity 8th Annual Global Cannabis Conference. The conference is...
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced results for the full year ending December 31, 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted. FY2023 Financial...
InterCure: Bargain Israel Cannabis Play
InterCure Ltd. has faced challenges due to the conflict with Hamas, including not having access to a prime facility in Israel, but is expected to recover. The cannabis market in Israel is still limited to medical use, with expansion to...
InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint
NEW YORK & HERZLIYA, Israel--(BUSINESS WIRE)---- $INCR #CANNABIS--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing...
PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape
LONDON--(BUSINESS WIRE)---- $INCR #CannG--The PESG Research has released an industry update following the regulatory shifts in Germany. Germany is expected to pass the Cannabis Act today (Friday), heralding a transformative era for the medical cannabis industry. This legislative milestone, by...
InterCure Provides an Update Regarding Nir Oz Facility
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Compan y"), the leading medical cannabis company in Israel and outside of North America, reports today that, further...
Source: https://incomestatements.info
Category: Stock Reports